Amplify Cybersecurity ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? Amplify Cybersecurity ETF trades at $123.68 (market cap $3.55B), while Relay Therapeutics Inc. Common Stock trades at $17.39 (market cap $3.94B). The key difference: Amplify Cybersecurity ETF and Relay Therapeutics Inc. Common Stock are close in size by market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Relay Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 30 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| HACK | RLAY | |
|---|---|---|
Market Cap | $3.55B | $3.94B |
Volume | 233,961 | 3,432,928 |
Sector | Sector/Thematic | Health |
52-Week High | $127.66 | $20.75 |
52-Week Low | $70.69 | $6.03 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | — | $3.06B |
Signals from Pluang's Aura AI — not financial advice
HACK trades at $125.81, down 1.45% today but near its 52-week high, with a strong technical outlook showing bullish moving averages and key support at $124. Recent news highlights the ETF's momentum, driven by AI safety concerns and cybersecurity demand, with the fund up 84.96% from its 52-week low. Financial ratios are not disclosed for this ETF, but sector growth remains a tailwind.
The outlook for HACK is positive, supported by rising cybersecurity spending and AI-driven threats, though risks include increased short interest and sector volatility. Analyst sentiment is bullish, with the ETF positioned to benefit from ongoing digital security trends, but investors should monitor competitive and macroeconomic pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →